References
- Derkay CS, Bluher AE. Update on recurrent respiratory papillomatosis. Otolaryngol Clin North Am. 2019;52(4):669–679.
- Novakovic D, Cheng ATL, Zurynski Y, et al. A prospective study of the incidence of Juvenile-Onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018;217(2):208–212.
- Omland T, Akre H, Lie KA, et al. Risk factors for aggressive recurrent respiratory papillomatosis in adults and juveniles. Angeletti PC, ed. PLoS One. 2014;9(11):e113584.
- Omland T, Lie KA, Akre H, et al. Recurrent respiratory papillomatosis: HPV genotypes and risk of high-grade laryngeal neoplasia. PLoS One. 2014;11;9(6):e99114.
- Evers G, Schliemann C, Beule A, et al. Long-Term Follow-Up on systemic bevacizumab treatment in recurrent respiratory papillomatosis. Laryngoscope. 2020;31;131(6):E1926-E1933
- Vargas SO, Healy GB, Rahbar R, et al. Role of vascular endothelial growth factor-A in recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2005;114(4):289–295.
- Best SR, Mohr M, Zur KB. Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope. 2017;127(10):2225–2229.
- Bedoya A, Glisinski K, Clarke J, et al. Systemic bevacizumab for recurrent respiratory papillomatosis: a single center experience of two cases. Am J Case Rep. 2017;18:842–846.
- Best SR, Friedman AD, Landau-Zemer T, et al. Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2012;121(9):587–593.
- Zeitels SM, Barbu AM, Landau-Zemer T, et al. Local injection of bevacizumab (avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol. 2011;120(10):627–634.
- Ryan MA, Leu GR, Upchurch PA, et al. Systemic bevacizumab (avastin) for Juvenile-Onset recurrent respiratory papillomatosis: a systematic review. Laryngoscope. 2021;131(5):1138–1146.
- Nagel S, Busch C, Blankenburg T, et al. Behandlung der respiratorischen papillomatose kasuistik zur systemischen therapie mit Bevacizumab1. Pneumologie. 2009;63(7):387–389.
- Carnevale C, Ferrán-De la Cierva L, Til-Pérez G, et al. Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children. Laryngoscope. 2019;129(4):1001–1004.
- Cuestas G, Rodríguez V, Doormann F, et al. Tracheobronchial and pulmonary papillomatosis without involvement of the larynx treated with intravenous bevacizumab in a child. Arch Argent Pediatr. 2019;117(1):E72–E76.
- Pogoda L, Ziylan F, Smeeing DPJ, et al. Bevacizumab as treatment option for recurrent respiratory papillomatosis: a syste™matic review. Eur Arch Otorhinolaryngol. 2022;279(9):4229–4240.
- Rosenberg T, Philipsen BB, Mehlum CS, et al. Therapeutic use of the human papillomavirus vaccine on recurrent respiratory papillomatosis: a systematic review and meta-analysis. J Infect Dis. 2019;219(7):1016–1025.
- Sidell DR, Balakrishnan K, Best SR, et al. Systemic bevacizumab for treatment of respiratory papillomatosis: international consensus statement. Laryngoscope. 2021;131(6):E1941-E1949
- Derkay CS, Wikner EE, Pransky S, et al. Systemic use of bevacizumab for recurrent respiratory papillomatosis: who, what, where, when, and why? Laryngoscope. 2022;133(1):2–3